Souhaitez-vous accéder aux communiqués récents ?

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

MORRISTOWN, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Piston Bio LLC, a clinical-stage biotechnology company developing therapeutics targeting neuroimmune mechanisms in cancer, today announced the...

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Sangamo has now submitted the ST-920 preclinical and clinical modules to the FDA for review.

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for...

BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling...

This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...

Totaligent (OTCID: TGNT) signed a binding LOI with GloMed Solutions, a Japanese medical aesthetics and biologics distribution company

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer